你好!欢迎访问 登录|立即注册

0576-88813233

|
当前位置:科瑞产品

CFG920

CFG920 1260006-20-9
规格 价格 库存 数量
在线咨询 大包装询价 加入购物车
如您需要更多数量的报价,请点击立即获取报价或者通过电子邮件sales@crene.cn把您需要的数量信息提交给我们我们会在第一时间回复您,谢谢!
产品信息
产品名称:CFG920 纯度:99% min
CAS NO:1260006-20-9 溶解度:Soluble in DMSO
分子式:C14H13ClN4O 包装:可按客户要求包装
分子量:C14H13ClN4O 贮存:-20℃
质量控制
备注说明

CFG920 is a CYP17 inhibitor, is also an orally available inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential antiandrogen and antineoplastic activities. Upon oral administration, CYP17 inhibitor CFG920 inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells.

 

中文名称:

1-(2-氯-4-吡啶基)-3-(4-甲基-3-吡啶基)-2-咪唑烷酮


英文名称:

1-(2-Chloro-4-pyridinyl)-3-(4-methyl-3-pyridinyl)-2-imidazolidinone

参考文献

1: Gomez L, Kovac JR, Lamb DJ. CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids. 2015 Mar;95:80-7. doi: 10.1016/j.steroids.2014.12.021. Epub 2015 Jan 3. Review. PubMed PMID: 25560485; PubMed Central PMCID: PMC4323677.

2: Yin L, Hu Q, Hartmann RW. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78. doi: 10.3390/ijms140713958. Review. PubMed PMID: 23880851; PubMed Central PMCID: PMC3742227.

版权所有 Copyright(C) 2018-2024 台州市科瑞生物技术有限公司

技术支持:kerui  浙ICP备09021343号-1
公司所列产品中涉及到专利,只供研发使用,不做销售;管制产品将严格遵守中国法律和购买客户国法律的规定销售,所有产品都不适用于人用 如被销售到构成专利侵权的国家,则相应的一切风险将由买方承担。